New hope for hard-to-treat blood cancers: experimental drug imetelstat tested in phase 2 trial

NCT ID NCT05583552

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes or acute myeloid leukemia that did not improve after standard therapy. The goal is to see if the drug can improve blood cell counts and control the disease. Participants who respond can continue treatment until the disease worsens.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Nantes - Hôtel Dieu

    Nantes, France

  • CHU de Toulouse

    Toulouse, France

  • Hôpital Archet 1

    Nice, France

  • Hôpital Saint-Louis

    Paris, France

  • Klinikum rechts der Isar

    München, Germany

  • Linear Clinical Research

    Nedlands, Australia

  • Marien Hospital Düsseldorf

    Düsseldorf, Germany

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Brisbane and Women's Hospitals

    Brisbane, Australia

  • Universität Jena, Medizinische Fakultät

    Jena, Germany

  • Universität Leipzig, Medizinische Fakultät

    Leipzig, Germany